Effectiveness of Oral Semaglutide on Glucose Control and Body Weight Up to 18 Months: a Multicenter Retrospective Real-World Study

Oral semaglutide, an innovative orally administered GLP-1 receptor agonist for type 2 diabetes (T2D) management was herein evaluated for its effectiveness in a multi-center retrospective real-world study. We included new-users of oral semaglutide from 18 specialist care centres and collected retrospective data on baseline clinical characteristics. Updated values of HbA1c and body weight were analyzed using the mixed model for repeated measures. The study included 166 individuals with T2D, predominantly men (64.5